Results 151 to 160 of about 7,117 (221)

Clinical practice guidelines for the diagnosis and management of chronic lymphocytic leukemia in Saudi Arabia: consensus statement by an expert panel. [PDF]

Front Med (Lausanne)
Alotaibi G, Aleem A, Absi A, Alaskar AS, Alfraih F, Alhejazi A, Almasari A, Alzahrani MF, Motabi I, El Fakih R.   +9 more
europepmc   +1 more source

The Development of Novel Therapies for Chronic Lymphocytic Leukaemia in the Era of Targeted Drugs. [PDF]

J Clin Med
Robak T, Iskierka-Jażdżewska E, Puła A, Robak P, Puła B.   +4 more
europepmc   +1 more source

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

Journal of Clinical Oncology, 2021
PURPOSE Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy tolerability.
John C Byrd, Peter Hillmen, Paolo Ghia
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Acalabrutinib

Reactions Weekly
  +15 more sources

Acalabrutinib

Reactions Weekly, 2023
  +7 more sources

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia.

New England Journal of Medicine
BACKGROUND Whether fixed-duration acalabrutinib-venetoclax (with or without obinutuzumab) would result in better progression-free survival than chemoimmunotherapy in patients with untreated chronic lymphocytic leukemia (CLL) is unknown. METHODS In this
Jennifer R. Brown, J. Seymour, Wojciech Jurczak, Andrew Aw, M. Wach, Árpád Illés, Alessandra Tedeschi, Carolyn Owen, A. Skarbnik, Daniel Lysák, K. Eom, M. Šimkovič, M. Pavlovsky, A. Kater, B. Eichhorst, Kara Miller, V. Munugalavadla, T. Yu, M. de Borja, P. Ghia   +19 more
semanticscholar   +1 more source

Response-adapted Phase 2 study of acalabrutinib window prior to frontline chemotherapy in untreated large B-cell lymphoma: Molecular correlates of response to acalabrutinib

Blood
Background: Large B-cell lymphoma (LBCL) is characterized by genetic heterogeneity that confers a differential response to therapy. Pre-clinical models and clinical studies of BTK inhibitors (BTKi) in relapsed LBCL suggest preferential activity in ...
M. Roschewski, James D. Phelan, R. Lakhotia, C. Melani, Stefania Pittaluga, Disha Dalela, D. Huang, Julius C Enssle, George W. Wright, Max J. Gordon, Sarah Evans, Maria Lindenberg, Esther Mena, Elaine S Jaffe, Louis M. Staudt, Wyndham H Wilson   +15 more
semanticscholar   +1 more source

Comparing real-world treatment patterns and outcomes of zanubrutinib and acalabrutinib in CLL/SLL at University of California academic health centers.

Journal of Clinical Oncology
e23263 Background: Newer BTK inhibitors zanubrutinib (ZANU) and acalabrutinib (ACA) are preferred over first-generation ibrutinib for chronic lymphocytic leukemia (CLL) treatment due to better toxicity profiles shown in randomized controlled ...
Aryan Ayati, G. Maglinte, Marjan Massoudi, Qianhong Fu, Rhys Williams, M. Seshadri, Vivek A Rudrapatna, Michelle Wang   +7 more
semanticscholar   +1 more source